At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01530 3SBIO
Not Yet Opened 12-11 16:08:03
27.560
-0.320
-1.15%
High28.280Low27.020Vol18.44M
Open28.140D1 Closing27.880Amplitude4.52%
Mkt Cap69.95BTradable Cap69.95BTotal Shares2.54B
T/O506.85MT/O Rate0.73%Tradable Shares2.54B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
3SBIO (01530) Issues 105 Million Shares Under Placement Agreement
Stock News  ·  12-09 20:14
3SBIO (01530) Issues 105 Million Shares Under Placement Agreement
3SBio Raises HK$3.1 Billion Through Private Share Placement
Reuters  ·  12-09 20:06
3SBio Raises HK$3.1 Billion Through Private Share Placement
HK Stock Movement | 3SBIO (01530) Drops Nearly 5% After Raising Over HK$3 Billion in Placement, Plans Spin-off of Minde International
Stock News  ·  12-09 14:08
HK Stock Movement | 3SBIO (01530) Drops Nearly 5% After Raising Over HK$3 Billion in Placement, Plans Spin-off of Minde International
CMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2
Stock News  ·  12-09 10:14
CMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2
Assessing 3SBio (SEHK:1530)’s Valuation After a Recent Pullback in Share Price
Simply Wall St.  ·  12-06
Assessing 3SBio (SEHK:1530)’s Valuation After a Recent Pullback in Share Price
BOCOM INTL: China's 1st-8th Batch National Drug Procurement Renewal Rules Likely Moderate, Short-Term Catalysts Ample
Stock News  ·  12-05
BOCOM INTL: China's 1st-8th Batch National Drug Procurement Renewal Rules Likely Moderate, Short-Term Catalysts Ample
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
Stock News  ·  12-03
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
Short Selling Statistics for Hong Kong Stocks | December 3
Stock News  ·  12-03
Short Selling Statistics for Hong Kong Stocks | December 3
BUZZ-HK-listed 3SBIO slips on discounted share sale
Reuters  ·  12-02
BUZZ-HK-listed 3SBIO slips on discounted share sale
3SBio Seeks HK$3.12 Billion via Share Sale
MT Newswires Live  ·  12-02
3SBio Seeks HK$3.12 Billion via Share Sale
BRIEF-3SBio To Place 105.2 Million Shares
Reuters  ·  12-02
BRIEF-3SBio To Place 105.2 Million Shares
3SBIO (01530) Plans 6.50% Discounted Share Placement to Raise Approximately HK$3.087 Billion
Stock News  ·  12-02
3SBIO (01530) Plans 6.50% Discounted Share Placement to Raise Approximately HK$3.087 Billion
3SBio - to Place 105.2 Mln Shares at HK$29.62 per Placing Share
THOMSON REUTERS  ·  12-02
3SBio - to Place 105.2 Mln Shares at HK$29.62 per Placing Share
3SBio Inc. Announces Private Placement of 105 Million New Shares
Reuters  ·  12-02
3SBio Inc. Announces Private Placement of 105 Million New Shares
Zhixintong HK Morning Brief | 2025 Brain-Computer Interface Conference to Open in Shanghai This Week; Silver Prices Hit Record High
Stock News  ·  12-02
Zhixintong HK Morning Brief | 2025 Brain-Computer Interface Conference to Open in Shanghai This Week; Silver Prices Hit Record High
While institutions invested in 3SBio Inc. (HKG:1530) benefited from last week's 6.5% gain, individual investors stood to gain the most
Simply Wall St.  ·  11-29
While institutions invested in 3SBio Inc. (HKG:1530) benefited from last week's 6.5% gain, individual investors stood to gain the most
GTHT Securities Maintains "Overweight" Rating on 3SBIO (01530), Cites Spin-off as Catalyst for Mindy's Accelerated Growth
Stock News  ·  11-27
GTHT Securities Maintains "Overweight" Rating on 3SBIO (01530), Cites Spin-off as Catalyst for Mindy's Accelerated Growth
Guosen Securities Maintains "Outperform" Rating on 3SBIO (01530), Highlights Two Key Phase 3 Clinical Studies
Stock News  ·  11-27
Guosen Securities Maintains "Outperform" Rating on 3SBIO (01530), Highlights Two Key Phase 3 Clinical Studies
China Universal Asset Management Increases Stake in 3SBIO (01530) by 1.162 Million Shares at HK$29.82 per Share
Stock News  ·  11-26
China Universal Asset Management Increases Stake in 3SBIO (01530) by 1.162 Million Shares at HK$29.82 per Share
HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%
Tiger Newspress  ·  11-26
HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%
No data available

Introduction

Company Name.
3SBIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
3SBio Inc is an investment holding company principally engaged in the development, production, marketing and sale of biopharmaceutical products. The Company's main products include biopharmaceuticals such as TPIAO, EPIAO, Yisaipu, and Cipterbin, as well as small moleculessuch as Mandi and Remitch. The Company is also engaged in the contract development and manufacturing operations (CDMO) business that provides customers with research, development and production of a variety of biopharmaceuticals and therapeutic technology platform services. The Company's products are mainly used for chemotherapy-induced thrombocytopenia (CIT), anemia caused by chronic kidney disease (CKD), treatment of chemotherapy-induced anemia (CIA), ankylosing spondylitis (AS) and psoriasis. The Company mainly operates its businesses in the domestic and overseas markets.
Issue price:
--